Navigation Links
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Date:5/21/2009

NCE V and is based upon the proven design of the MULTI-LINK(R) family of stents. Abbott plans to make XIENCE PRIME available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions. XIENCE PRIME is pending CE Mark and is not available for sale.

"XIENCE PRIME builds upon the unprecedented body of clinical evidence from the SPIRIT family of clinical trials, and offers advances in the delivery system and an enhanced stent design to make the stent even easier for physicians to deliver to the lesion site," said Robert Hance, president, Abbott Vascular. "We are pleased with the progress we've made to bring this next advancement to physicians and patients, and we look forward to launching XIENCE PRIME in Europe later this year."

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION stent. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. It is also under review with Health Canada. '/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
2. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
3. Spirit II explores long-term performance of XIENCE V stent
4. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
5. FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System
6. Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
7. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
8. Siemens Demonstrates Groundbreaking Approach to Stroke Diagnosis at ASNR 2009
9. Concord Coalition Says New Trustees Report Demonstrates the Importance of Health Care Cost Control
10. Ben-Gurion U of the Negev study demonstrates link between appetite and elderly mortality
11. New Research Demonstrates that Wild Blueberries May Support Cardiovascular Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... Emirates (PRWEB) July 12, 2014 Dubai ... Angeles basketball legend is heading to the UAE. ... six-time champion will be in the UAE from 28-31 ... Weekend in support of diabetes awareness. The event is ... entertainment marketing and event management company based in Dubai. ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... Just another AccessorySCARBOROUGH, N.Y., March 4 No hair? ... ( BaldGirlsDoLunch.org ) brings women with alopecia areata ... heads will turn. That delights founder Thea Chassin ... hair normally. It,s time for everyone to understand it ...
... logged on to www.WorldMedAssist.com to help him find the surgeon in ... of ICU with his mitral valve replacement overseas completed. He,s now home ... ... -- When Henry Konczak first learned that his chronic fatigue was due to ...
... its advanced mobile health screening services to the ... and techniques in the industry, HealthYes! screens its clients for ... peripheral artery disease and osteoporosis. , ... ...
... detect and measure pneumothoraces in trauma patients helps physicians ... room settings, according to a study performed at Massachusetts ... , "With the rapid development of ... trauma patients replaced traditional x-ray radiography in emergency care ...
... the Journal of Clinical Endocrinology & Metabolism , ... of clinical medicine and director of the Diabetes Clinical ... with age. An estimated 37 million Americans over the ... population. Another 20 to 30 percent of seniors, an ...
... Healthcare Sustainability for America,s Hospitals and Medical ... Healthcare Waste and Emergency Preparedness Coalition (CleanMedWaste.org) ... provide education about two major problems facing ... operational sustainability during a crisis and the ...
Cached Medicine News:Health News:Seattle's First Bald Girls Do Lunch(R) 2Health News:Seattle's First Bald Girls Do Lunch(R) 3Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 2Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 3Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 2Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 3Health News:Computer-aided system effectively detects and measures pneumothoraces in chest trauma patients 2Health News:'Pre-diabetics' face heightened risk of heart disease 2Health News:The Healthcare Waste and Emergency Preparedness Coalition Announces Its Official Formation 2
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: